Resolved hepatitis B is associated with higher reactivation risk than chronic infection after chemoembolization for hepatocellular carcinoma

Table 3 Predictors of hepatitis B virus reactivation

Variables	Univariate		Multivariable
	HR (95%CI)	P value	HR (95%CI)	P value
Age (years)	0.984 (0.958-1.010)	0.218
Male sex	1.159 (0.602-2.229)	0.659
Cirrhosis	1.432 (0.573-3.577)	0.443
Child-Pugh score, B/C	1.308 (0.523-3.269)	0.566
Baseline HBV DNA detectable	0.905 (0.545-1.501)	0.698
HBV DNA (log10 IU/mL)	0.924 (0.816-1.046)	0.210
TACE sessions, three or more	0.813 (0.483-1.369)	0.437
Albumin (g/dL)	0.810 (0.502-1.306)	0.387
Platelets (× 109/L)	0.998 (0.993-1.002)	0.361
AFP (log10 ng/mL)	1.429 (1.123-1.817)	0.004	1.325 (1.039-1.691)	0.024
PIVKA-II (log10 mAU/mL)	1.221 (0.815-1.830)	0.333
AST (U/L)	0.998 (0.988-1.008)	0.754
ALT (U/L)	1.000 (0.993-1.007)	0.986
HBsAg positive	1.757 (0.913-3.379)	0.091
Anti-HBc positive	1.891 (1.132-3.159)	0.015
HBeAg positive	1.103 (0.596-2.039)	0.755
Resolved HBV infection1	4.019 (2.038-7.925)	< 0.001	3.982 (1.990-7.968)	< 0.001
Total TACE sessions	0.925 (0.794-1.078)	0.320
Tumor size (cm)	1.141 (1.048-1.243)	0.002	1.077 (0.977-1.189)	0.137
Hypertension	0.682 (0.369-1.262)	0.223
Diabetes mellitus	0.849 (0.442-1.633)	0.624
Total bilirubin (mg/dL)	0.894 (0.475-1.684)	0.729
INR	3.437 (0.646-18.293)	0.148

Univariable and multivariable Cox proportional hazards regression analyses were performed. Variables with P < 0.05 in univariable analysis were included in the multivariable model.

¹Hepatitis B surface antigen negative, antibody to hepatitis B core antigen positive.

HR: Hazard ratio; CI: Confidence interval; HBV: Hepatitis B virus; TACE: Transarterial chemoembolization; AFP: Alpha-fetoprotein; PIVKA-II: Protein induced by vitamin K absence or antagonist-II; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; HBsAg: Hepatitis B surface antigen; anti-HBc: Antibody to hepatitis B core antigen; HBeAg: Hepatitis B e antigen; INR: International normalized ratio.